Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Bullboard - Stock Discussion Forum Appili Therapeutics Inc T.APLI

Alternate Symbol(s): APLIF

Healthcare

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Add To Watchlist

TSX:APLI - Post Discussion

Appili Therapeutics Inc > Appili Therapeutics Announces Non-Convertible Secured Loan

View:

Post by Betteryear2 on Mar 29, 2022 2:23pm

Appili Therapeutics Announces Non-Convertible Secured Loan

March 29, 2022 07:36 AM Eastern Daylight Time

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has entered into a senior secured loan and exclusive license and distribution agreement (the “Agreement”) with Long Zone Holdings Inc. (“LZH”), led by Jonathan Ross Goodman, founder of both Paladin Labs Inc. and Knight Therapeutics Inc. (TSE: GUD). The US$3.6 million senior secured loan will be used by Appili to retire the previously announced senior convertible funding agreement with The Lind Partners and for working capital purposes.

https://www.businesswire.com/news/home/20220328005914/en/

173